Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.
about
A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.HIV-specific CD8⁺ T cells and HIV eradicationIL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors.IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma.The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments.A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance.Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent.Immune microenvironment of experimental rat C6 gliomas resembles human glioblastomas.Environmental stimuli shape microglial plasticity in glioma.Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control.ALT-803 Transiently Reduces Simian Immunodeficiency Virus Replication in the Absence of Antiretroviral Treatment.The potential and promise of IL-15 in immuno-oncogenic therapies.Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas.IL-2 and Beyond in Cancer Immunotherapy.Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade.Regulatory T cells (Tregs): A major immune checkpoint to consider in combinatorial therapeutic HIV-1 vaccines.Interleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells.One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.
P2860
Q30385378-8BC7B3B8-5BF9-45AB-93E5-9862ECCD7014Q36515071-EADA052F-4348-4FAB-BB77-403C5350FA99Q36917882-C360CC0C-1293-4362-B9CA-8CC11FE4509AQ37085973-37025C78-56CB-452E-A7E6-B9B90940841DQ38438763-51588FB1-8E7C-44C7-B9FC-68AA4A1E1D6DQ38670431-C71609FC-A3BB-4174-A430-162C10AE14FFQ38744668-163D3421-14E7-40F7-8001-DD7B1175B801Q39531973-37FD93C6-17AC-4014-B5CA-52098E532E66Q40049630-0DEED0F3-AB56-43B4-9A42-36FC7F639964Q47135965-DE8B7D95-7F5C-4790-B845-098769AF901BQ47235650-42691A7F-C305-495C-ADFB-D8FC34E36C19Q47568646-86E87254-1BE6-4250-A68F-ED68E4E54A83Q47585968-0CCC9550-5339-49E9-AFFE-BDBF31E4DED9Q49216382-1F6419C9-5E6D-4DAA-8ED0-6B927BD0F59AQ49672464-50D450E0-824D-4173-8C5B-7CBBF6F06777Q50004232-C5553103-F2E0-4FEF-8A0A-6B575F488D6CQ50423292-8A8BE7F9-5E6E-4335-A9E3-FBF7523FC0B7Q50424105-92E1E540-A196-4D07-AD82-931B0D5FE27AQ52329640-9F86253D-671B-42BF-9B96-A86CAB0D1165Q55332380-EC11ADE3-FB06-4813-917E-6E51C8C5F3FB
P2860
Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Therapeutic administration of ...... n a murine glioblastoma model.
@ast
Therapeutic administration of ...... n a murine glioblastoma model.
@en
type
label
Therapeutic administration of ...... n a murine glioblastoma model.
@ast
Therapeutic administration of ...... n a murine glioblastoma model.
@en
prefLabel
Therapeutic administration of ...... n a murine glioblastoma model.
@ast
Therapeutic administration of ...... n a murine glioblastoma model.
@en
P2093
P2860
P356
P1476
Therapeutic administration of ...... n a murine glioblastoma model.
@en
P2093
Chul-Kee Park
Dimitrios Mathios
Drew M Pardoll
Emily K Jeng
Hing C Wong
Michael Lim
Peter R Rhode
Sarah Alter
Warren D Marcus
P2860
P304
P356
10.1002/IJC.29686
P577
2015-07-14T00:00:00Z